Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.
P. Mulvenna,Matthew Nankivell,Rachael Barton,Corinne Faivre-Finn,P. Wilson,Elaine McColl,Barbara Moore,Iona Brisbane,David Ardron,Tanya Holt,Sally Morgan,C. Lee,Kathryn Waite,Neil A Bayman,C. Pugh,Benjamin Sydes,Richard Stephens,Mahesh K.B. Parmar,Ruth E Langley +18 more
TLDR
Significantly more episodes of drowsiness, hair loss, nausea, and dry or itchy scalp were reported while patients were receiving WBRT, although there was no evidence of a difference in the rate of serious adverse events between the two groups.About:
This article is published in The Lancet.The article was published on 2016-10-22 and is currently open access. It has received 521 citations till now. The article focuses on the topics: Palliative care & Randomized controlled trial.read more
Citations
More filters
Journal ArticleDOI
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
Silvia Novello,Fabrice Barlesi,Raffaele Califano,Raffaele Califano,Tanja Cufer,Simon Ekman,M. Giaj Levra,Keith M. Kerr,Sanjay Popat,Martin Reck,Suresh Senan,G Simo,Johan Vansteenkiste,Sanne Peters +13 more
TL;DR: The ESMO Guidelines Committee concluded that current state-of-the-art oncology practices in France, Belgium, and the Netherlands are suitable for frontline use and recommend further research into these practices.
Journal ArticleDOI
The Microenvironmental Landscape of Brain Tumors
TL;DR: A number of distinct features of the brain tumor microenvironment are discussed, including brain-resident cell types, the blood-brain barrier, and various aspects of the immune-suppressive environment.
Journal ArticleDOI
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
Thanyanan Reungwetwattana,Kazuhiko Nakagawa,Byoung Chul Cho,Manuel Cobo,Eun Kyung Cho,Alessandro Bertolini,Sabine Bohnet,Caicun Zhou,Ki Hyeong Lee,Naoyuki Nogami,Isamu Okamoto,Natasha B. Leighl,Rachel Hodge,Astrid McKeown,Andrew P. Brown,Yuri Rukazenkov,Suresh S. Ramalingam,Johan Vansteenkiste +17 more
TL;DR: Osimertinib has CNS efficacy in patients with untreated EGFR-mutated non-small-cell lung cancer and these results suggest a reduced risk of CNS progression with osimert inib versus standard EGFR -TKIs.
Journal ArticleDOI
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001.
Paul D. Brown,Vinai Gondi,Stephanie L. Pugh,Wolfgang A. Tomé,Jeffrey S. Wefel,Terri Armstrong,Joseph Bovi,Cliff G. Robinson,Andre Konski,Deepak Khuntia,David R. Grosshans,Tammie L.S. Benzinger,Deborah Watkins Bruner,Mark R. Gilbert,David Roberge,Vijayananda Kundapur,Kiran Devisetty,Sunjay Shah,Kenneth Y. Usuki,Bethany Anderson,Baldassarre Stea,Harold Yoon,Jing Li,Nadia N. Laack,Tim J. Kruser,Steven J. Chmura,Wenyin Shi,Snehal Deshmukh,Minesh P. Mehta,Lisa A. Kachnic +29 more
TL;DR: HA-WBRT plus memantine better preserves cognitive function and patient-reported symptoms, with no difference in intracranial PFS and OS, and should be considered a standard of care for patients with good performance status who plan to receive WBRT for brain metastases with no metastases in the HA region.
Journal ArticleDOI
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Yi-Long Wu,Myung-Ju Ahn,Marina Chiara Garassino,Ji Youn Han,Nobuyuki Katakami,Hye Ryun Kim,Rachel Hodge,Paramjit Kaur,Andrew P. Brown,Dana Ghiorghiu,Vassiliki A. Papadimitrakopoulou,Tony Mok +11 more
TL;DR: Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC, and was reported the first comparative evidence of osimert inib CNS efficacy compared with platinum- pemetrexe from a phase III study.
References
More filters
Journal ArticleDOI
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
Jacques Ferlay,Isabelle Soerjomataram,Rajesh Dikshit,Sultan Eser,Colin Mathers,Marise Souto Rebelo,Donald Maxwell Parkin,David Forman,Freddie Bray +8 more
TL;DR: The GLOBOCAN series of the International Agency for Research on Cancer (IARC) as mentioned in this paper provides estimates of the worldwide incidence and mortality from 27 major cancers and for all cancers combined for 2012.
Journal Article
EuroQol : a new facility for the measurement of health-related quality of life
Journal ArticleDOI
Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials
Laurie E. Gaspar,Charles E. Scott,Marvin Rotman,Sucha O. Asbell,Theodore L. Phillips,Todd H. Wasserman,W. Gillies McKenna,Roger W. Byhardt +7 more
TL;DR: An analysis of tumor/patient characteristics and treatment variables in previous Radiation Therapy Oncology Group (RTOG) brain metastases studies was considered necessary to fully evaluate the benefit of these new interventions.
Journal ArticleDOI
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
David W. Andrews,Charles B. Scott,Paul W. Sperduto,Adam E. Flanders,Laurie E. Gaspar,Michael C. Schell,Maria Werner-Wasik,W. Demas,J. Ryu,Jean-Paul Bahary,Luis Souhami,Marvin Rotman,Minesh P. Mehta,Walter J. Curran +13 more
TL;DR: WBRT and stereotactic radiosurgery should, therefore, be standard treatment for patients with a single unresectable brain metastasis and considered for Patients with two or three brain metastases.
Journal ArticleDOI
Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System
Jill S. Barnholtz-Sloan,Andrew E. Sloan,Faith G. Davis,Fawn D. Vigneau,Ping Lai,Raymond E. Sawaya +5 more
TL;DR: Total IP% of brain metastases was lower than previously reported, and it varied by primary site, race, sex, age at diagnosis of primary cancer, and SEER stage ofPrimary cancer.